Literature DB >> 21922028

Selective-serotonin reuptake inhibitors for the treatment of hypersensitive esophagus.

Nikos Viazis1, George Karamanolis, Eleni Vienna, Dimitrios G Karamanolis.   

Abstract

In patients with proton-pump inhibitor (PPI) resistant reflux symptoms, ambulatory 24 h pH impedance monitoring can be used to assess whether a relationship exists between symptoms and reflux episodes. Using this technique it has been suggested that patients with typical reflux symptoms and a normal upper endoscopy should be subclassified as follows: normal endoscopy and abnormal distal acid esophageal exposure (patients with acid reflux); normal endoscopy, with normal distal acid esophageal exposure and a positive symptom association for either acid or nonacid reflux (patients with hypersensitive esophagus); and normal endoscopy, normal distal acid esophageal exposure and a negative symptom association for acid and nonacid reflux (patients with functional heartburn). Although for patients with a normal endoscopy and abnormal distal acid esophageal exposure more aggressive acid suppression can be recommended, managing patients with hypersensitive esophagus and functional heartburn remains a real challenge.Therefore, investigators have evaluated the role of tricyclic antidepressants or selective-serotonin reuptake inhibitors (SSRIs) in influencing esophageal perception. Imipramine has been shown to decrease pain perception in healthy male volunteers and improve symptoms of patients with chest pain and normal coronary angiograms. Trazodone improved symptoms in patients with esophageal contraction abnormalities, while administration of SSRIs lowered chemical and mechanical sensitivity and benefited patients with diffuse esophageal spasm. Furthermore, in a recent study conducted by our group, citalopram administered once daily for 6 months was effective in a select group of patients with hypersensitive esophagus, suggesting that there is a role for SSRIs in the treatment of this disorder.

Entities:  

Keywords:  gastroesophageal reflux disease; hypersensitive esophagus; selective-serotonin reuptake inhibitors

Year:  2011        PMID: 21922028      PMCID: PMC3165206          DOI: 10.1177/1756283X11409279

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  31 in total

Review 1.  Visceral pain-peripheral sensitisation.

Authors:  G F Gebhart
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

2.  Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.

Authors:  M F Vela; L Camacho-Lobato; R Srinivasan; R Tutuian; P O Katz; D O Castell
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

Review 3.  Nonerosive reflux disease--current concepts and dilemmas.

Authors:  R Fass; M B Fennerty; N Vakil
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

4.  Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans.

Authors:  J Tack; D Broekaert; B Coulie; B Fischler; J Janssens
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

Review 5.  The enteric nervous system.

Authors:  R K Goyal; I Hirano
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

6.  Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach.

Authors:  M Handa; K Mine; H Yamamoto; H Hayashi; O Tsuchida; F Kanazawa; C Kubo
Journal:  J Clin Gastroenterol       Date:  1999-04       Impact factor: 3.062

7.  Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study.

Authors:  Nikos Viazis; Anastasia Keyoglou; Alexandros K Kanellopoulos; George Karamanolis; John Vlachogiannakos; Konstantinos Triantafyllou; Spiros D Ladas; Dimitrios G Karamanolis
Journal:  Am J Gastroenterol       Date:  2011-05-31       Impact factor: 10.864

Review 8.  Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia.

Authors:  A P S Hungin; C Hill; A Raghunath
Journal:  Aliment Pharmacol Ther       Date:  2009-08-15       Impact factor: 8.171

9.  Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial.

Authors:  R E Clouse; P J Lustman; T C Eckert; D M Ferney; L S Griffith
Journal:  Gastroenterology       Date:  1987-04       Impact factor: 22.682

10.  Imipramine decreases oesophageal pain perception in human male volunteers.

Authors:  P L Peghini; P O Katz; D O Castell
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

View more
  7 in total

Review 1.  Functional heartburn: definition and management strategies.

Authors:  Frank Zerbib; Stanislas Bruley des Varannes; Mireille Simon; Jean Paul Galmiche
Journal:  Curr Gastroenterol Rep       Date:  2012-06

2.  Feasibility and acceptability of esophageal-directed hypnotherapy for functional heartburn.

Authors:  M E Riehl; J E Pandolfino; O S Palsson; L Keefer
Journal:  Dis Esophagus       Date:  2015-03-30       Impact factor: 3.429

Review 3.  Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis.

Authors:  Rahul Mittal; Luca H Debs; Amit P Patel; Desiree Nguyen; Kunal Patel; Gregory O'Connor; M'hamed Grati; Jeenu Mittal; Denise Yan; Adrien A Eshraghi; Sapna K Deo; Sylvia Daunert; Xue Zhong Liu
Journal:  J Cell Physiol       Date:  2017-04-10       Impact factor: 6.384

Review 4.  Symptomatic reflux disease: the present, the past and the future.

Authors:  Guy Boeckxstaens; Hashem B El-Serag; André J P M Smout; Peter J Kahrilas
Journal:  Gut       Date:  2014-03-07       Impact factor: 23.059

5.  Republished: symptomatic reflux disease: the present, the past and the future.

Authors:  Guy Boeckxstaens; Hashem B El-Serag; André J P M Smout; Peter J Kahrilas
Journal:  Postgrad Med J       Date:  2015-01       Impact factor: 2.401

6.  The effect of adding duloxetine to lansoprazole on symptom and quality of life improvement in patients with gastroesophageal reflux diseases: A randomized double-blind clinical trial.

Authors:  Marjan Mokhtare; Arezoo Chaharmahali; Mansour Bahardoust; Atefeh Ghanbari; Arash Sarveazad; Roozbeh Naghshin; Farbod Abbaskhanidavanloo
Journal:  J Res Med Sci       Date:  2021-01-28       Impact factor: 1.852

Review 7.  Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders.

Authors:  Nicola de Bortoli; Salvatore Tolone; Marzio Frazzoni; Irene Martinucci; Giulia Sgherri; Eleonora Albano; Linda Ceccarelli; Cristina Stasi; Massimo Bellini; Vincenzo Savarino; Edoardo V Savarino; Santino Marchi
Journal:  Ann Gastroenterol       Date:  2018-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.